Castle Biosciences Inc (NASDAQ: CSTL)’s stock price has gone decline by -1.45 in comparison to its previous close of 19.31, however, the company has experienced a -7.76% decrease in its stock price over the last five trading days. globenewswire.com reported 2025-04-30 that Patients identified as low risk by DecisionDx-Melanoma had a 2.8% sentinel lymph node (SLN) positivity rate, well below the National Comprehensive Cancer Network® (NCCN) guidelines’ 5% threshold to forgo sentinel lymph node biopsy (SLNB) surgery FRIENDSWOOD, Texas, April 30, 2025 (GLOBE NEWSWIRE) — Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new study in Cancer Diagnosis & Prognosis demonstrating that DecisionDx-Melanoma outperforms both American Joint Committee on Cancer (AJCC) staging and the CP-GEP test (clinicopathological and gene expression profiling model) in identifying patients at low risk of SLN positivity who may consider forgoing SLNB surgery.1 “When relying on genomic testing to guide critical decisions about procedures like SLNB, a test must demonstrate exceptional accuracy in identifying patients with minimal risk of metastasis,” said Peter A. Prieto, M.D.
Is It Worth Investing in Castle Biosciences Inc (NASDAQ: CSTL) Right Now?
Castle Biosciences Inc (NASDAQ: CSTL) has a price-to-earnings ratio that is above its average at 31.05x. The stock has a 36-month beta value of 1.14. Opinions on the stock are mixed, with 8 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CSTL is 27.98M, and at present, short sellers hold a 5.23% of that float. On May 02, 2025, the average trading volume of CSTL was 419.99K shares.
CSTL’s Market Performance
CSTL’s stock has seen a -7.76% decrease for the week, with a -5.75% drop in the past month and a -32.68% fall in the past quarter. The volatility ratio for the week is 4.27%, and the volatility levels for the past 30 days are at 6.18% for Castle Biosciences Inc The simple moving average for the past 20 days is -5.64% for CSTL’s stock, with a -28.41% simple moving average for the past 200 days.
Analysts’ Opinion of CSTL
Many brokerage firms have already submitted their reports for CSTL stocks, with Guggenheim repeating the rating for CSTL by listing it as a “Buy.” The predicted price for CSTL in the upcoming period, according to Guggenheim is $25 based on the research report published on December 14, 2023 of the previous year 2023.
Scotiabank, on the other hand, stated in their research note that they expect to see CSTL reach a price target of $54. The rating they have provided for CSTL stocks is “Sector Outperform” according to the report published on January 05th, 2023.
Stephens gave a rating of “Overweight” to CSTL, setting the target price at $59 in the report published on January 07th of the previous year.
CSTL Trading at -8.25% from the 50-Day Moving Average
After a stumble in the market that brought CSTL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.90% of loss for the given period.
Volatility was left at 6.18%, however, over the last 30 days, the volatility rate increased by 4.27%, as shares surge +0.70% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -26.10% lower at present.
During the last 5 trading sessions, CSTL fell by -6.33%, which changed the moving average for the period of 200-days by -1.00% in comparison to the 20-day moving average, which settled at $20.18. In addition, Castle Biosciences Inc saw -28.59% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CSTL starting from MAETZOLD DEREK J, who sale 4,408 shares at the price of $21.52 back on Apr 21 ’25. After this action, MAETZOLD DEREK J now owns 4,275 shares of Castle Biosciences Inc, valued at $94,851 using the latest closing price.
MAETZOLD DEREK J, the Pres. & Chief Exec. Officer of Castle Biosciences Inc, sale 1,236 shares at $21.52 during a trade that took place back on Apr 21 ’25, which means that MAETZOLD DEREK J is holding 74,627 shares at $26,596 based on the most recent closing price.
Stock Fundamentals for CSTL
Current profitability levels for the company are sitting at:
- 0.03 for the present operating margin
- 0.8 for the gross margin
The net margin for Castle Biosciences Inc stands at 0.05. The total capital return value is set at 0.02. Equity return is now at value 4.31, with 3.54 for asset returns.
Based on Castle Biosciences Inc (CSTL), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at 2.46. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is 15.03.
Currently, EBITDA for the company is 38.14 million with net debt to EBITDA at -2.45. When we switch over and look at the enterprise to sales, we see a ratio of 1.38. The receivables turnover for the company is 6.48for trailing twelve months and the total asset turnover is 0.63. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.29.
Conclusion
To sum up, Castle Biosciences Inc (CSTL) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
